Story perspectives
WHO Prioritizes Three Ebola Therapies; Brazil Risk Minimal
6/1/2026
1 of 1
Story summary
- WHO prioritised three experimental treatments for Bundibugyo Ebola.
- Sao Paulo assessed Ebola risk to Brazil and South America as very low.
- Regeneron says maftivimab is already in the Democratic Republic of Congo for immediate use.
- Oxford's ChAdOx1 vaccine may be testable in 2-3 months, while IAVI's rVSV vaccine is not expected for trials for 7-9 months.
